Teva moves to buy Mylan
pharmafile | April 21, 2015 | News story | Research and Development, Sales and Marketing | India, Mylan, Perrigo, Teva, US, Vigodman, generics, israel, merger
Israeli generics drug giant Teva has made an offer to buy its US rival Mylan for around $40.1 billion.
The move which represents a transaction valued at $82.00 per Mylan share and comprised of approximately half cash and half stock, would create the world’s biggest generic drug company should it go through.
What is surprising also about this potential acquisition is that Mylan is itself in the process of offering to pay the over-the-counter drug specialist Perrigo $28 billion to acquire its business.
But for Teva, which has estimated the move could generate $2 billion annually in cost and tax savings, this detail is not insurmountable – in fact it’s a good thing and offers a better alternative according to Erez Vigodman, Teva’s chief executive.
“Our proposal would provide Teva stockholders with very attractive strategic and financial benefits and Mylan stockholders with a substantial premium and immediate value for their shares, as well as the opportunity to participate in the significant upside potential of the combined company – one that would transform the global generics space and leverage it to hold a unique leadership position in the pharmaceutical industry,” Vigodman says.
The firm’s chairman Professor Yitzhak Peterburg backs this up in its statement, adding that the bid is strongly supported by the Teva board whose strategy has been to ‘aggressively pursue growth opportunities’ that advance its goal of being a stronger, diversified organisation.
Only this month the proposed deal of Mylan buying Perrigo was itself seen as producing a “global pharmaceutical leader with an unmatched commercial and operating platform”, with the combined company said to have a stock market value nearing $60 billion.
Now this latest big generics potential merger follows in the wake of Sun Pharma that has just recently closed its mega merger deal with fellow Indian giant Ranbaxy, and began the integration of the two businesses.
Mylan’s object of desire Perrigo also splashed its cash just last year when it purchased fellow OTC drugmaker Omega, taking on its $1.3 billion worth of debt in a deal estimated around $4.5 billion.
But this complicated chain could well lead to the latest big tie-up in the pharmaceutical industry, where the expiry of patents (Copaxone in Teva’s case) from best-selling drugs forces its hand to reach out.
Vigodman adds: “The combination of Teva and Mylan is a truly unique opportunity to build upon both companies’ solid foundations. Bringing the two together will create a much stronger, more efficient platform to achieve our goals.”
Brett Wells
Related Content
Teva announces positive results from trial of AJOVY for migraine
Teva has announced positive results from the phase 4 PEARL study of AJOVY (fremanezumab), its …
Sharp invests $100m in US and EU manufacturing and packaging facilities
Sharp Services, a pharmaceutical packaging and sterile manufacturing specialist, has announced investments totalling $100m across …
Moderna doses first US patient in phase 1 trial of mRNA-4106 for solid tumours
The START Center for Cancer Research has dosed the first US participant in Moderna’s phase …
